Trexquant Investment LP Decreases Holdings in Disc Medicine, Inc. $IRON

Trexquant Investment LP decreased its position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 33.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,556 shares of the company's stock after selling 4,318 shares during the period. Trexquant Investment LP's holdings in Disc Medicine were worth $425,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Amalgamated Bank raised its holdings in shares of Disc Medicine by 38.6% in the first quarter. Amalgamated Bank now owns 787 shares of the company's stock worth $39,000 after buying an additional 219 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after buying an additional 266 shares during the period. Arizona State Retirement System grew its position in shares of Disc Medicine by 12.5% in the first quarter. Arizona State Retirement System now owns 5,315 shares of the company's stock valued at $264,000 after purchasing an additional 590 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Disc Medicine by 9.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 6,934 shares of the company's stock valued at $344,000 after purchasing an additional 624 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Disc Medicine in the fourth quarter valued at about $40,000. Hedge funds and other institutional investors own 83.70% of the company's stock.

Insiders Place Their Bets

In other Disc Medicine news, CEO John D. Quisel sold 34,800 shares of the firm's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $55.33, for a total value of $1,925,484.00. Following the sale, the chief executive officer directly owned 161,828 shares in the company, valued at approximately $8,953,943.24. This trade represents a 17.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Kevin Bitterman sold 2,287 shares of the firm's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $61.03, for a total value of $139,575.61. Following the completion of the sale, the director owned 590,621 shares in the company, valued at $36,045,599.63. The trade was a 0.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 132,913 shares of company stock valued at $7,856,571. Company insiders own 3.64% of the company's stock.

Disc Medicine Stock Up 1.9%

IRON stock opened at $61.91 on Tuesday. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $68.73. The company has a current ratio of 32.11, a quick ratio of 32.11 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $2.15 billion, a P/E ratio of -13.85 and a beta of 0.77. The firm has a 50 day simple moving average of $58.62 and a 200-day simple moving average of $52.09.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.41). On average, equities research analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

IRON has been the topic of several research reports. HC Wainwright reissued a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a research note on Thursday, July 3rd. Wedbush restated an "outperform" rating and issued a $90.00 price objective on shares of Disc Medicine in a report on Monday, July 21st. Truist Financial assumed coverage on shares of Disc Medicine in a report on Monday, July 21st. They set a "buy" rating and a $86.00 price target for the company. Morgan Stanley boosted their price objective on shares of Disc Medicine from $85.00 to $90.00 and gave the stock an "overweight" rating in a research report on Monday, August 18th. Finally, Raymond James Financial began coverage on shares of Disc Medicine in a research report on Wednesday, June 11th. They issued a "strong-buy" rating and a $89.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the company. Based on data from MarketBeat, Disc Medicine presently has a consensus rating of "Buy" and an average price target of $98.30.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Want to see what other hedge funds are holding IRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Disc Medicine, Inc. (NASDAQ:IRON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.